Heptares Therapeutics (Heptares) recently announced the grant of multiple key patents in the United States relating to its GPCR-focused drug discovery platform.
MRC Technology is inviting potential partners with early stage RNA, DNA and/or protein-based diagnostics to submit details and explore collaborative partnerships.
MRC Technology is a member of the newly launched Knowledge Quarter, set up to create a vibrant knowledge hub by bringing together organisations that are actively involved in the advancement and dissemination of knowledge.
MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of…
New partnership with Yabao Pharmaceutical Co, Inc. to discover, develop and commercialise innovative compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson’s disease.
The Neurodegeneration Medicines Acceleration Programme (Neuro-MAP), led by medical research charity MRC Technology, will see charities and funding bodies identify promising drug projects no longer in development and help scientists to take them forward to the next stage. Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s could be revived.
Congratulations to Catherine Kettleborough, MRC Technology's Associate Director of Drug Discovery Biology, who has been elected to…
Project will investigate a small molecule solution for Macrophage migration inhibitory factor
London, UK, 29 September 2014: MRC Technology (MRCT), a UK medical research charity, today announced the appointment…